Endo terminates acquisition agreements with Somerset Therapeutics and Wintac Ltd. Endo subsidiaries Ventures Limited, Par Pharmaceutical and Par Formulations Private, have terminated their respective agreements to acquire Somerset Therapeutics, a New Jersey based specialty pharmaceutical company, and the business of its India-based affiliate Wintac Limited, which operates as Somerset Therapeutics’ contract developer and manufacturer. There are no penalties or other payments associated with terminating the agreements.
https://thefly.com/landingPageNews.php?id=2871733
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.